Repligen Corporation (NASDAQ:RGEN) Holdings Lowered by Zevenbergen Capital Investments LLC

Key Points

• Zevenbergen Capital Investments LLC reduced its stake in Repligen Corporation by 22.3%, selling 25,160 shares and currently holding 87,587 shares worth $11,145,000.
• Barclays and Stephens have given overweight ratings on Repligen, with target prices of $150 and $160 respectively, while the stock currently has an average price target of $169.45.
• Repligen reported a quarterly earnings miss, with an EPS of $0.37, below the expected $0.40, although its revenue increased by 14.8% year-over-year to $182.37 million.

Zevenbergen Capital Investments LLC trimmed its stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 22.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 87,587 shares of the biotechnology company's stock after selling 25,160 shares during the quarter. Zevenbergen Capital Investments LLC owned about 0.16% of Repligen worth $11,145,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in RGEN. Price T Rowe Associates Inc. MD raised its holdings in shares of Repligen by 11.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock worth $1,027,165,000 after purchasing an additional 743,815 shares in the last quarter. Champlain Investment Partners LLC raised its holdings in shares of Repligen by 8.6% in the 4th quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company's stock worth $222,176,000 after purchasing an additional 122,595 shares in the last quarter. Conestoga Capital Advisors LLC raised its holdings in shares of Repligen by 3.4% in the 1st quarter. Conestoga Capital Advisors LLC now owns 980,247 shares of the biotechnology company's stock worth $124,727,000 after purchasing an additional 32,665 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in shares of Repligen by 183.1% in the 4th quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company's stock worth $132,227,000 after purchasing an additional 594,189 shares in the last quarter. Finally, New York State Common Retirement Fund raised its holdings in shares of Repligen by 7.6% in the 1st quarter. New York State Common Retirement Fund now owns 625,388 shares of the biotechnology company's stock worth $79,574,000 after purchasing an additional 43,946 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Barclays assumed coverage on shares of Repligen in a report on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 target price on the stock. Stephens upgraded shares of Repligen to an "overweight" rating and set a $160.00 target price on the stock in a report on Tuesday, July 22nd. JPMorgan Chase & Co. cut their price target on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a report on Tuesday, April 29th. Wells Fargo & Company cut their price target on shares of Repligen from $180.00 to $175.00 and set an "overweight" rating on the stock in a report on Wednesday, July 30th. Finally, Wolfe Research upgraded shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target on the stock in a report on Tuesday, April 29th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $169.45.

Repligen Stock Performance

Shares of RGEN opened at $111.43 on Friday. The company's 50 day moving average price is $122.76 and its 200 day moving average price is $134.36. Repligen Corporation has a 52 week low of $102.96 and a 52 week high of $182.52. The company has a market capitalization of $6.26 billion, a PE ratio of -445.70, a PEG ratio of 2.05 and a beta of 1.05. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.65%. The company had revenue of $182.37 million for the quarter, compared to analysts' expectations of $174.62 million. During the same period in the previous year, the firm posted $0.40 earnings per share. The business's revenue for the quarter was up 14.8% on a year-over-year basis. Research analysts expect that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.